According to Entera Bio's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.62069. At the end of 2023 the company had a P/E ratio of -1.94.
Year | P/E ratio | Change |
---|---|---|
2023 | -1.94 | 19.31% |
2022 | -1.62 | -73.53% |
2021 | -6.13 | 273.23% |
2020 | -1.64 | -28.72% |
2019 | -2.30 | -0.52% |
2018 | -2.32 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.